` PIQ (Proteomics International Laboratories Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

PIQ
vs
S&P/ASX 300

Over the past 12 months, PIQ has underperformed S&P/ASX 300, delivering a return of -60% compared to the S&P/ASX 300's 7% growth.

Stocks Performance
PIQ vs S&P/ASX 300

Loading

Performance Gap
PIQ vs S&P/ASX 300

Loading
PIQ
S&P/ASX 300
Difference

Performance By Year
PIQ vs S&P/ASX 300

Loading
PIQ
S&P/ASX 300
Add Stock

Competitors Performance
Proteomics International Laboratories Ltd vs Peers

S&P/ASX 300
PIQ
0KHE
TMO
DHR
207940
Add Stock

Proteomics International Laboratories Ltd
Glance View

Market Cap
51.7m AUD
Industry
Life Sciences Tools & Services

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.

PIQ Intrinsic Value
0.329 AUD
Overvaluation 17%
Intrinsic Value
Price
Back to Top